On December 13, 2021 AskAt reported that it received an Official Decision of Grant dated November 19, 2021 of a use patent for its EP4 receptor antagonist in the treatment of NASH-associated liver cancer (Press release, AskAt, DEC 13, 2021, View Source [SID1234596829]). The notice was issued by the Russian Federal Service for Intellectual Property, Patents and Trademarks (Rospatent), in connection with Russian Patent Application No. 2020109376 (Filing Date: November 2, 2017). In addition to Russia, the use patent has been granted in Canada, China, Europe, Japan, Mexico, and the U.S.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!